We need to determine if management discusses a larger next stage that they are already operating toward, and whether the first stage is already real with concrete current activity. The question asks for a specific trajectory: present producing and bigger next stage as working assumption. Looking at the transcript, there are several potential trajectories. For example, aflibercept 8 mg: they have submitted BLA, expect launch late August. But that's not yet launched, so first stage not real. Dupixent: ongoing growth, but that's steady growth. Oncology: they have data, but many are in trials. The costim bispecifics: they have early data, but still in trials. The COVID antibody: not yet in clinic. The most promising might be the Libtayo expansion: they have approval and are launching, with plans to expand. But is there a "larger next stage" they are operating toward? They mention expanding into more indications and geographies, but that's typical growth. Another: odronextamab and linvoseltamab: they plan regulatory submissions in second half, but not yet approved. So first stage not real. The question asks: "On this call, does management talk about a LARGER NEXT STAGE of the company's business as something it is ALREADY OPERATING TOWARD — planning, preparing, scheduling, staffing, producing, or making decisions on the working assumption that this bigger stage is coming — AND is the FIRST STAGE of that same trajectory ALREADY REAL today, with management pointing to concrete current activity (actual orders, customers, shipments, deployments, work, output, or usage happening now) that the larger stage grows directly out of?" We need to find a specific example where they have current real activity and they are planning a larger continuation. For instance, they mention "we are preparing for a potential U.S. launch for aflibercept 8 milligrams in late August" but that's not yet launched. They have EYLEA currently, but that's a different product. The trajectory might be from EYLEA to aflibercept 8 mg, but EYLEA is already established, and the 8 mg is a new product, not a larger stage of the same activity? Actually, it's a continuation of the retinal franchise. But the first stage (EYLEA) is real, and the larger stage (8 mg) is coming. However, is management "operating toward" it? They are preparing for launch, but it's conditional on approval. They say "potential U.S.
Regeneron Pharmaceuticals, Inc.
The call grade, management's tone measured against 177,437 other calls, what changed since the quarter before, and every one of the 500 checks.
This is the current report. Unlock its call read, expected move size, and all 500 answers.
- Are there more than eight analyst questioners?
- Does the operator announce more than five questioners?
- Does the operator announce more than ten questioners in the Q&A?
- Is there a questioner from an investment bank other than the first three analysts who ask questions?
30 markers, measured against 177,437 calls
Language counted straight from the transcript, behaviour read by the 500 checks, tone above. The band is the middle half of every call we have graded; a flag means this call sits outside it.
All 500 AI checks
Q2 2026 · 500 checks
Every answer is below. Open any check to see what its YES or NO means.
YES Does an executive answer a question by describing a process rather than an outcome?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Is there a question the executive answers with a question back to the analyst?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone compare the company to an unnamed "competitor" or "peer" rather than naming it?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone use "historically" or "traditionally" while defending a current practice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Is a departure, transition, or role change mentioned only in passing without a thank-you or tribute?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone reference a private conversation ("as I told...", "as we discussed offline")?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the transcript contain the phrase "next question" at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an analyst ask a question spanning more than five sentences?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any analyst ask a question containing multiple sub-questions (three or more)?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the CEO answer a question personally after another executive initially responds?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any speaker use the phrase "if you look at" at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any analyst preface a question by summarizing the company's stated results?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any speaker use the word "obviously" at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone say "guidance" in the same sentence as a specific number?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any analyst say "congrats" or "congratulations" to management?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Is the word "scale" or "scaling" used as a verb?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does an analyst ask a question beginning with a number ("two questions", "three quick ones")?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any analyst say "thank you" before asking their question?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any analyst name two or more executives when asking their question?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "outperform," "outperformance," or "beat" appear?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone say "the environment" when describing market conditions?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any executive use the word "momentum" at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does an executive begin an answer with "Great question," "Thanks," or "Appreciate"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the CFO use the phrase "adjusted" or "non-GAAP" at least three times?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any speaker say "thank you" more than three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any speaker say "with that" as a transition phrase?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone use the phrase "on a comparable basis" or "adjusted for"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any speaker say "moving to" or "turning to" when changing topics?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any speaker say "over to you" or "I'll turn it over"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any speaker say "operator" aloud during the call?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone repeat the same stock phrase three or more times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone use the phrase "as you know" to introduce a claim?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any speaker apologize without attaching a fix to the apology?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the call end without any closing statement from the CEO?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Is there a request to move the call along or to the last question?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an executive answer a question with another question?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does an executive mention the weather?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone describe a negotiation currently in progress?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an executive describe a competitor with anything resembling respect?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the operator announce more than ten questioners in the Q&A?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone use the phrase "kind of" at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any question include the word "color"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the CEO deliver the opening remarks rather than the CFO or IR head?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone say "if I may" or "if you don't mind"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any executive's first sentence include the word "revenue"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does an analyst use the word "clarification" or "clarify" in a question?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any question contain the phrase "color on" or "some color"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the operator use the phrase "our final question" before closing?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone say "let me" at least three times?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "aggressive" or "aggressively" appear at least once?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does an analyst ask a question referencing "the puts and takes"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone use the phrase "to be clear"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does an analyst's question include a compliment followed by "but"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the CFO use the word "sequential" or "sequentially" at least once?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any speaker say "with that" at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone say "for the benefit of" or "just to remind" when restating context?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone use the phrase "early days"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "journey" appear?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the speaker describe a strategy as "disciplined" without describing any trade-off?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Is there an apology offered to a specific analyst by name?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone use the phrase "to be honest" or "frankly"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone promise to "follow up" or "take that offline" and fail to commit to when?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone on the call interrupt a colleague mid-sentence?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does someone use a personal anecdote rather than a metric to justify confidence?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the word "question" appear in the operator's speech more than three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "growth" appear at least ten times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone use the phrase "a couple of"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does an analyst ask about capital allocation or buybacks?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does management use the word "strong" at least three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an executive use the phrase "we're seeing" at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the word "opportunity" appear at least three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does management use the word "confident" or "confidence" at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the phrase "record" appear at least twice in the transcript?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the word "team" appear at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does management promise to follow up or take a question offline?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any speaker say "we're excited about" or "we're pleased with"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Do two or more analysts from the same firm ask questions?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone use the phrase "moving forward" or "go forward"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does management mention a specific number of stores, locations, or markets?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone use the word "folks"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone say "thank you" more than five times in total?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does an executive use the phrase "we believe"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the operator use the phrase "next question" at least three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any analyst mention a specific percentage figure in their question?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "quarter" appear in at least ten questions or answers during the Q&A?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does at least one analyst ask a question about margins or costs?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the CEO answer the majority of analyst questions personally?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any analyst ask a question phrased as "Can you talk about" or "Can you speak to"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the CFO speak during the Q&A portion at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any question reference a specific quarter (e.g., "fourth quarter") by name?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the operator interrupt the Q&A to announce time is limited or that this will be the last question?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any analyst ask a question beginning with "just" (e.g., "just curious")?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any analyst ask about a specific dollar amount or number stated in the prepared remarks?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any question begin with the words "can you" or "could you"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any executive use the phrase "if you look at" during the Q&A?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the CFO answer at least one question without the CEO speaking first?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any analyst ask a question containing an explicit comparison to a competitor company?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the phrase "moving on" or "next question" come from the operator?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does an analyst ask about capital allocation (capex, buybacks, M&A, or dividends) in one question?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the phrase "color" appear (e.g., "add some color") in the transcript?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "guidance" appear at least five times in the transcript?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any question contain the word "why"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any speaker say "I think" at least three times within a single answer?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any executive begin an answer by restating the analyst's name?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any executive's answer exceed 300 words in the transcript?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the CEO answer the first analyst question personally?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "obviously" appear in the transcript?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the transcript contain the word "margin" more than ten times?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does an executive begin an answer with "So" as the first word?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the phrase "if I may" or "if I could" appear?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any executive say "let me" at least once?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any question contain the word "specifically"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does management use the word "momentum" at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does management mention "margin" or "margins" in prepared remarks?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Is the word "definitely" used by any speaker?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "seasonality" appear?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone use the word "robust" to describe demand, growth, or the pipeline?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone use the word "leverage" as a verb at least once?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any executive use the word "team" when referring to employees?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any executive say "that said" or "having said that" to introduce a caveat?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does an analyst's question include the phrase "going forward"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an executive say "great question" at any point?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone say "we remain confident" or "we are confident"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any executive say "thank you" immediately after finishing an answer?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does an executive cite a specific dollar figure greater than one billion?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any analyst's question contain the word "curious"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does an analyst reference a specific prior quarter by name (e.g., "last quarter")?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any speaker say "obviously" two or more times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any analyst ask a follow-up in the same turn after their first answer?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any analyst ask about a specific geographic region or market?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any analyst ask a question that includes the phrase "long term" or "long-term"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "margin" or "margins" appear at least five times?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the word "opportunity" or "opportunities" appear at least three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does an executive say "we'll come back to that" or defer an answer to a follow-up?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone say "thank you" three or more times in the Q&A section?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the CFO use the phrase "free cash flow" at least once?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any executive use the word "momentum"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the CEO mention at least one specific customer segment by name (e.g., "enterprise")?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the phrase "take your question" or "take the question" appear?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any analyst introduce themselves by name before asking their first question?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone say "including" at least three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does management reference "the macro environment" or "macroeconomic" at least once?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any executive reference "our team" or "the team" at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the operator announce more than one analyst from the same firm?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any prepared remark mention "headwinds" or "tailwinds"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any speaker say "with that, I'll turn it over"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the CFO use the phrase "capital allocation"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does an executive decline to answer, citing that something will come later or is not disclosed?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an analyst ask a two-part question containing the word "but"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone ask a follow-up question in the same turn after their first question is answered?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone answer "yes" or "no" as the first word of a response?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone say "thank you" at least ten times in the transcript?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does an executive use the phrase "if you look at" at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any analyst begin their question with "Hi" or "Hello" as a greeting?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone say "we are excited about" without naming a number?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an analyst reference a peer company's results or valuation?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any speaker use the phrase "just to clarify" or "just to be clear"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does management use the word "headwind" or "headwinds"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any speaker use the word "tailwind" or "tailwinds"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any speaker use the word "momentum"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "investments" appear in the context of margins or costs?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone mention "FX" or "foreign exchange"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "efficiency" or "productivity" appear at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does an analyst thank the executives or congratulate them before asking a question?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does an executive say "great question" or "thanks for the question"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an executive say "as we said last quarter" or reference a prior call?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the phrase "going forward" appear at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does management use the word "levers" when discussing actions?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does management thank analysts by name at any point after a question?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone say "we'll take that offline" or offer to follow up after the call?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does management use the word "committed" regarding a target?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the CEO's prepared remarks mention "macro" or "macroeconomic"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone use the phrase "the vast majority"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the word "temporary" or "transitory" appear?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Is an analyst's question answered with "great question" or similar?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Is there a questioner from an investment bank other than the first three analysts who ask questions?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any analyst ask a question that includes a reference to a specific dollar figure?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone say "thank you" at least ten times across the call?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the phrase "thank you for taking my question" or "thanks for taking my question" appear?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any analyst's first sentence contain a compliment or thanks before asking their question?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the CFO present in both the prepared remarks and the Q&A portion of the call?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the CEO personally deliver the closing remarks of the call?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the CEO's prepared remarks contain the word "team" at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any speaker use the phrase "moving on" or "with that" to transition between topics?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the phrase "in terms of" appear at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO First-person singular ("I believe," "I think") used more by the CFO than the CEO.
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES A single question receives answers from two different executives.
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES A hedge word ("maybe," "sort of") appears inside a direct quantitative claim.
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any speaker use the word "obviously"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the word "guidance" appear in both prepared remarks and the Q&A section?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any executive defer a question to another executive by name?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Someone uses the word "honestly," "frankly," or "to be clear."
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone use the word "ecosystem" or "platform" without a number attached?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the transcript contain the word "certainly" three or more times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone begin an answer by restating or paraphrasing the analyst's name?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does an analyst reference a competitor by name during their question?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does a speaker say "let me" at least twice in the transcript?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES The transcript contains an apology unrelated to financial results.
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO The word "challenge" is spoken more often than "opportunity."
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "seasonality" or "seasonal" appear?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO The phrase "as you know" appears at least twice.
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any speaker use the word "challenge" or "challenges" at least three times?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone mention "weather" as a factor affecting results?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does an executive say "thank you" to the analyst before answering a question?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any speaker say "great question" or similar praise of a question?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO The final question is answered noticeably shorter than the opening ones.
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone say "we remain" followed by a verb (e.g., "we remain committed")?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does an executive cite a conversation with a customer that has no verifiable specificity (unnamed, undated, unquantified)?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the transcript contain a sentence that begins with "What I would say is"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any question mention a specific percentage or dollar figure?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the CEO personally answer more questions than any other executive?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the operator say "our final question" or similar?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "opportunity" or "opportunities" appear at least five times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the word "clearly" appear at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "leverage" appear as a verb at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any analyst's first name get used by an executive when thanking them?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the operator announce more than five questioners?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Are there more than ten analyst questions in total?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the operator use the phrase "our next question comes from" more than three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Are the CEO's prepared remarks longer than the CFO's, judged by speaker turns on the transcript page?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does management say "we are not going to comment on" or equivalent refusal language?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Executive corrects an analyst's premise.
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the CFO's prepared section exceed the CEO's in number of paragraphs?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the CEO personally answer more than half of the analyst questions?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any analyst mention the word "margin" in their first question?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Executive uses the word "excited" more than twice.
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any analyst ask a multi-part question containing three or more distinct questions?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "guidance" appear at least three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any analyst ask a two-part question signaled by "and also" or "and secondly"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does an analyst begin with a compliment, such as "great quarter" or "congrats"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an executive say "we said" when recalling prior statements?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any analyst begin their turn with "thanks" or "thank you"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "headwind" or "tailwind" appear at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "synergies" appear?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any analyst address a question to two or more executives by name?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "capital" appear at least five times?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any executive say "we feel" rather than "we believe" or "we think"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "capital" appear in at least three different speakers' turns?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does an executive use the phrase "over time" at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does an executive say "as I mentioned" or "as we said" at least once?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the CEO open the call before any analyst questions by mentioning the macro environment?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone say "we are pleased" or "we're excited"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone use the word "leverage" (financial or metaphorical)?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an analyst thank management before asking their question?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Is the word "automation" or "productivity" used at least once?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the word "uncertainty" or "uncertainties" appear at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the phrase "year over year" appear at least three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does management use the word "leverage" or "leveraging" at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Currency headwinds mentioned unprompted.
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Is the phrase "a number of" used at least once?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone use the phrase "best-in-class" or "industry-leading"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "momentum" appear at least twice in prepared remarks?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Is the phrase "on a constant currency basis" or similar currency adjustment used?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an analyst's question include the phrase "just to clarify"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the phrase "the team" appear at least twice in management remarks?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any speaker say "so clearly" or "quite frankly"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does management use the phrase "we believe" at least three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Speaker says "we don't guide" on anything.
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the CFO use the word "quarter" at least ten times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any speaker say "thank you" more than five times in total?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "macro" or "macroeconomic" appear at least twice in the call?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the transcript contain the word "typically" at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does an executive state they will "come back to" a question or follow up later?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does management thank analysts for their questions at any point during Q&A?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Speaker admits being surprised by anything.
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any speaker use the phrase "going forward"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does management use the phrase "going forward" at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone say "stability" or "stable" when describing demand?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Word "normal" used about demand.
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does an executive say "stay tuned" or "more to come"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does management describe a cost program, restructuring, or efficiency initiative by a proper name?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the CFO's prepared section mention interest expense by name or figure?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "volatility" appear?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Executive mentions a hobby or personal anecdote.
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the word "pipeline" appear without a dollar figure attached?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the phrase "the macro" or "macro environment" appear?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the phrase "our team" appear at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does an executive say "great question" or "good question" at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any speaker say "we remain" followed by an adjective?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does management thank analysts by name when responding?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Is the word "flexibility" or "flexible" used at least once?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone say "takeaway," "take out," or "take rate"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Analyst compliments the team before asking a question.
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any speaker use "we're" where "we are" could substitute, more than twenty times overall?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any analyst reference the CEO or CFO by first name?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone say "obviously" at least three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone use the word "pipeline" at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone say "moving on" or "let me turn it over" during prepared remarks?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does an analyst ask a question starting with "just"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone say "headwind" or "headwinds" more than once?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does an analyst use the phrase "to clarify"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any executive use the phrase "year over year" at least three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does an executive cite a conversation with a customer, partner, or employee as evidence?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any question go to a named executive other than the CEO or CFO?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an executive say "to be clear" or "let me be clear"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone mention a competitor by name without being prompted?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Is there a question that management declines to answer directly, citing timing or disclosure constraints?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any question explicitly reference the company's prior guidance or outlook?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any speaker say "next question" or does the operator use the word "final" before the last question?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "invest" or "investment" appear at least five times in the transcript?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the CFO handle a strategic question instead of a financial one?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does an analyst flatter management within their first sentence of speaking?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an analyst ask two questions when told to ask only one?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone use the phrase "underlying" to modify a business metric?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone say "excited" or "pleased" at least twice in the transcript?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "guidance" appear in the prepared remarks (not just Q&A)?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Is the word "margin" used with a number attached (e.g., "400 basis points")?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the transcript contain the word "record" preceding a noun (e.g., "record margin")?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does an executive answer a question by citing a competitor's actions?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the word "macro" or "macroeconomic" appear in the transcript?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "challenges" appear more than once?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the CEO begin an answer with "look" or "listen"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the word "inflation" appear anywhere in the transcript?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Is there a pause or silence acknowledged on the call ("I think we lost you")?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does an executive name a specific competitor during the call?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the word "challenges" appear at least three times in the transcript?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone say "we don't break that out" in response to a question?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone describe a metric as "noisy" or "lumpy"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does an executive mention a specific number of percentage points when discussing market share?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does a speaker correct a figure they themselves just stated?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the CEO refer to a competitor by name rather than "competition" or "peers"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the CEO mention their own tenure or years of experience unprompted?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone use the phrase "the team" when taking ownership would be natural?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone blame weather, holidays, or calendar quirks unprompted?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone cite a personal anecdote involving a customer conversation?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone use the phrase "a little bit"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Is the CFO the speaker for at least one analyst question?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the word "guidance" appear in the transcript?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone say "we're excited" or "we are excited"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "dividend" appear?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Is the word "invest" or "investment" used more than twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "invest" or "investment" appear at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone cite a percentage of revenue from a specific segment?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "challenge" or "challenging" appear at least once?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone describe cutting discretionary spending like travel or hiring?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the phrase "year over year" appear?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the word "liquidity" appear at least once?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the transcript mention refinancing, maturity dates, or debt coming due?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone mention selling assets, real estate, or equipment to raise cash?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone reference "the macro" or "macro environment"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Is the word "capacity" mentioned?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone use the phrase "our customers" rather than naming a customer?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the transcript include a question about interest expense or debt service?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the phrase "working capital" appear in a context other than a seasonality excuse?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does management thank analysts at any point?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone reference borrowing from a bank or drawing on a credit facility?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "cost" appear in the first ten sentences of prepared remarks?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does an executive say "we remain confident" or similar?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone mention covenants, amendments to loan documents, or lender conversations?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone say "with that" or "that said" to pivot?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does an executive open their first answer by thanking the analyst?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any analyst's question include the word "capex" or "cash flow"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "headline" or "headwinds" appear at least once?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "core" appear at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does an analyst's turn contain the word "congratulations"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any analyst ask a question containing "how" and also "why"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any executive say "as we mentioned" or "as I mentioned" at least once?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Are there more than eight analyst questioners?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any analyst's question include a percentage figure?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any analyst's question contain the word "guidance"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the CFO's prepared remarks exceed 1,000 words?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any speaker say "if you look at"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the CEO personally answer the first question?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any speaker use the phrase "tailwind" or "tailwinds"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does management use the phrase "balance sheet" at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the CEO make closing remarks after the Q&A ends?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any speaker say "structurally" or "secular"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the operator say "our next question" two or more times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the final questioner get an explicit closing acknowledgment from the operator ("last question" or similar)?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does management use the phrase "business as usual" or "as expected" at least once?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does an analyst preface a question with "quick" or "quickly"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does an executive state a specific numeric percentage when answering a question?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone say "in terms of" at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Is there a question that clearly annoyed the executive, visible in the reply's abruptness?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "guidance" appear in the Q&A section?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the word "strong" appear more than five times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the phrase "thank you" appear more than ten times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an analyst ask a question containing the word "margin"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does management use the word "guidance" at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the phrase "thank you" appear at least ten times anywhere in the transcript?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does an executive begin an answer by restating the analyst's name?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any analyst ask about capital allocation or share repurchases?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "challenge" or "challenging" appear at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "opportunity" or "opportunities" appear more than three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Is there a villain—market conditions, regulation, currency—that behaves consistently across the call?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "challenging" appear?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "certainly" appear at least once in management's answers?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any analyst ask a personal, warm, or congratulatory question?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the phrase "capital" appear at least five times?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does an analyst ask a question the prepared remarks already answered?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the word "quarter" appear at least twenty times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any single analyst ask more than two questions during the whole call?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the phrase "on a year-over-year basis" or "year over year" appear at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Is the word "headwinds" or "tailwinds" used?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the word "margin" appear at least three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Is the word "confidence" or "confident" spoken by any executive?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone use the phrase "call it" or "let's call it" before an estimate?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the phrase "going forward" appear?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone say "coming back" or "circling back" to take a follow-up?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "inflation" appear at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any executive say "we believe" at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does management use the phrase "going forward"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does anyone use the word "robust"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any speaker use the phrase "if you will" or "so to speak"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any speaker say "appreciate" at least once?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone use the phrase "at the end of the day"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone tell a self-contained anecdote with a beginning, middle, and end?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any executive use the phrase "our team"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the transcript contain a silence, pause, or "we'll come back to that" that never resolves?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone describe a customer, employee, or competitor as a named character with a motive?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any executive say "we're pleased" or "I'm pleased"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Is there a moment of modesty—someone crediting luck or timing?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone use the phrase "on a year-over-year basis"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Is the word "excited" or "exciting" used by management at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any speaker say "just" five or more times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any question begin with "Can you" or "Could you"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "quick" or "quickly" appear in three or more analyst questions?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does an analyst ask for guidance on a metric management did not offer unprompted?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Is there a question about capital allocation (buybacks, M&A, debt, or dividends)?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any analyst use the word "clarify" or "clarification"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the word "obviously" appear at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does management refer to a prior call or prior quarter's commentary when answering?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone use the word "actually" at least three times?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any executive begin an answer with "Look," or "So,"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the word "challenging" or "challenges" appear at least three times?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the operator run out of queued questions and close early?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any analyst apologize or preface with "sorry" before asking?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Is the word "excited" used by the CEO more than the word "confident"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any speaker use the phrase "the right" before a noun ("the right team," "the right decisions")?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "guidance" appear more than five times in the transcript?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "tailwind" or "headwind" appear?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any analyst's question begin with a compliment or congratulation?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an analyst apologize before or during their question?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Are there more questions about revenue than about costs?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the word "challenging" appear at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any speaker use the phrase "on a" four or more times total (e.g., "on a constant currency basis")?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any executive answer begin with "Sure" or "Yes" followed by a comma?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone say "from a ... perspective" (e.g., "from a margin perspective")?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does an executive say "we're not going to" in response to a question?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does management decline to answer by citing a future event ("we'll address that in..." or "at our upcoming...")?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "quarter" appear at least 20 times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Is there a mention of "FX," "currency," or "foreign exchange"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any executive say "that's right" or "that's correct" to an analyst?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "leverage" appear at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Is the word "leverage" used at least three times?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does management use the word "headwinds" at least once?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any speaker say "great question" or thank the analyst before answering?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone attribute results to "the team" rather than to strategy?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any speaker say "going forward"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does any analyst begin their question with "congratulations"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an analyst thank management at the end of their turn?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does anyone describe the future with "We believe" more than "We expect"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does a speaker say "normal" or "normalized" about conditions that predate any disruption mentioned?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Is the word "momentum" used without a stated metric attached to it?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the word "macro" appear at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does management use the word "solid" at least once?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Is there an analogy to a machine, engine, or flywheel?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Is the word "visibility" used at least once?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Is the phrase "base case" or "scenario" used at least once?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does anyone say "we take that seriously" or "we're very focused on"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Is the phrase "to your point" or "as you mentioned" used at least once?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the operator say "thank you" more than three times?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does management mention a specific competitor by name?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does management say "the team" at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the word "fundamentally" appear at least once?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the phrase "ahead of" precede any mention of guidance or expectations?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does management use the phrase "on a year-over-year basis"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any single speaker say "right?" as a tag question at least once?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does management use the phrase "on a consistent basis" or "consistently"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does a speaker begin a sentence with "To be honest" or "To be clear"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does management use the phrase "strategic" at least twice?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any speaker describe a business unit as "healthy"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any speaker use the word "fundamentals"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the word "resilient" or "resilience" appear?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the operator mention a queue or "next question" more than three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does any analyst ask a follow-up after their initial answer ("follow-up", "second one", "just one more")?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any analyst ask a question containing the word "why"?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone say "if you look at" before citing a number?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the phrase "last question" or "final question" appear?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "clearly" appear anywhere in the transcript?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the CEO speak first among named executives in the Q&A?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the word "headwind" or "headwinds" appear at least twice?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does the CFO mention a specific percentage greater than ten?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the phrase "going forward" appear at least once?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "team" appear at least three times?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "confident" appear in any executive's remarks?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does an analyst thank management at the start or end of their turn?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does the CEO use the word "incredibly" at any point?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any executive use the word "team" to refer to company personnel?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does anyone say "to your point" when answering a question?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any executive say "with that" to transition between speakers or topics?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Does the word "transformation" or "transformational" appear?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any speaker say "moving on" or "next question" themselves?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any speaker use the word "hedging" or say "to hedge"?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
YES Does any analyst identify themselves with a two-part introduction (name and firm)?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
YES Does the word "talent" appear at least once?
The model found enough evidence in the earnings transcript to mark this exact condition as present.
NO Is the word "capacity" used more often about factories than about people?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does an executive confess to having too much of something physical somewhere?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Is a supplier or vendor mentioned by name at any point?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
NO Does any executive blame weather, season, or geography for a shipment or delivery issue?
The model did not find enough evidence in the earnings transcript to confirm this exact condition. NO means “not detected,” not necessarily “disproved.”
Archived AI reasoning
Earlier Artul research experiments on REGN calls. Open a question to read the model's original reasoning.
NO Operating in the future tense: management treats the next, larger stage of the business as already underway, and the fir
Original model output from the research archive. It may be verbose or include the model's working notes.
NO Operating without a net: management is running the company at a pace only justified if the next leg arrives
Original model output from the research archive. It may be verbose or include the model's working notes.
We need to determine if management describes a situation where the company has removed its own slack, is chasing something specific and already real, and names the exposure and stands behind it. The transcript is about Regeneron's Q4 2022 earnings call. We need to look for any such description. Key points: The company has many products and pipeline. The question asks about a specific part of its business where it has no fallback position. Let's scan the transcript for any mention of running without a buffer, single source, etc. I see mentions of manufacturing, supply, etc. But the question is about a deliberate arrangement where they are exposed if a near-term development doesn't go as expected. For example, they are preparing for aflibercept 8 mg launch, but that's not about removing slack. They have R&D expenses, but that's normal. Look for any statement about being "all in" on something, or having no backup. The transcript mentions "we are preparing for a potential U.S. launch for aflibercept 8 milligrams in late August" - that's not about removing slack. Maybe about COVID antibody? They are developing next-generation COVID antibody, but that's not a current business. The question is very specific: "management reveal that the company is currently operating WITHOUT A FALLBACK POSITION on a specific part of its business — that is, has it deliberately arranged its own operations so that it is exposed if a particular near-term development does not go the way management expects, and does management describe this exposure plainly and defend it rather than hedge it away?" We need to find if management says something like "we have no buffer" or "we are all in on this" etc. Looking at the transcript, there is a lot about pipeline, but nothing about removing slack. They talk about financial guidance, but that's not about operational slack. Maybe about the EYLEA franchise? They are facing competition, but they have EYLEA and aflibercept 8 mg. Not about removing slack. Perhaps about the Libtayo transaction? They bought back rights, but that's not about removing slack. I don't see any explicit statement about having no fallback. The company seems well-resourced with $11.6 billion cash. They are investing heavily but that's not the same as removing slack. The question requires all three conditions. Condition 1: The company has removed its own slack. I don't see that.
NO Cornered by one hard problem: management describes the company organized around solving a specific difficulty most other
Original model output from the research archive. It may be verbose or include the model's working notes.
We need answer YES/NO. Need analyze transcript. Need determine if management describes company organized around solving one particularly difficult problem others haven't solved, routinely fail at, or avoid, and currently succeeding in live operations. We need use only transcript. Need answer only YES or NO. Need be strict. Let's parse transcript. Company Regeneron. Management discusses multiple products: EYLEA, Dupixent, Libtayo, pipeline. Need identify if they frame a central hard problem they solve that others can't. They mention "internal R&D capabilities which has historically generated a high rate of return." "approximately 35 pipeline candidates." But no single named hard problem at center? They discuss "aflibercept 8 milligrams" potential standard of care, "unprecedented" extended dosing intervals. Dupixent in Type 2 diseases. Oncology pipeline. Next-gen COVID antibody targeting conserved epitope outside RBD. Gene therapy etc. Question asks: Does management describe company as organized around SOLVING ONE PARTICULARLY DIFFICULT PROBLEM THAT OTHERS IN ITS MARKET HAVE NOT SOLVED, ROUTINELY FAIL AT, OR AVOID ALTOGETHER — and convey currently succeeding at that hard thing in real, live operations? Need see if management's own words convey one coherent picture with both halves present as present-tense reality: (1) named hard problem at center; (2) company demonstrably doing it now, others not. Potential candidates: - "discovering drugs via genetics" maybe? They mention Regeneron Genetics Center, validated targets. But not framed as hard problem others fail at? They mention "R&D engine continues productivity." Not specific. - "developing best-in-class checkpoint inhibitors, bispecifics, costimulatory bispecifics" etc. They describe "truly magical in animal studies" and "first evidence" in humans. But is it a named hard problem? "Can we get this technology to work" for CNS siRNA? "challenging things to be first and to do something that nobody has ever done before." But that's still in development, not live operations. - "next-generation COVID-19 antibody" targeting conserved epitope outside RBD. They say unlike other neutralizing antibodies, retains activity against all variants because binds to conserved epitope. This is a hard problem others haven't solved? But they plan to initiate clinical trials this year; not currently succeeding in live operations.
NO Someone else's money is already committed to buy what this company makes
Original model output from the research archive. It may be verbose or include the model's working notes.
We need to determine if management explains forward business by pointing to budgets, funds, or spending commitments that other parties have already set aside. The question asks: does management convey that the money to pay for future volume is already allocated, approved, funded, or contractually earmarked outside the company, so that the buyer's decision is mainly where and when to spend, not whether. We need to examine the transcript for any such description. The call covers various products: EYLEA, Dupixent, Libtayo, aflibercept 8mg, oncology pipeline, etc. Management discusses growth, market share, approvals, launches, but do they point to external committed funds? For example, government programs, insurance reimbursements, or customer budgets already set aside? They mention "not-for-profit patient co-pay assistance fund" but that's about a temporary closure. They talk about "reimbursement" but not as a committed pool. They discuss "payer coverage and reimbursement issues" but not as a committed pool. They mention "global net sales" and "market penetration" but that's demand. The question specifically asks about "budgets, funds, or spending commitments that other parties have already set aside" and "must be spent on the kind of thing this company provides." For instance, if they said "we have a government contract that funds our product" or "insurance companies have allocated funds for this therapy" or "customers have approved capital budgets for this." None of that appears. They talk about "potential approvals" and "launches" but that's about regulatory and commercial execution. They also discuss "aflibercept 8 milligrams" and its potential to become standard of care, but that's about clinical profile, not about committed funds. They mention "Regeneron Genetics Medicine" and collaborations with Alnylam and Intellia, but those are partnerships, not external committed spending pools. They mention "COVID-19 antibody" but no government funding mentioned. They mention "capital expenditures" for their own facilities, but that's their own budget. They mention "share repurchase authorization" but that's their own capital return. Thus, no indication of external committed funds. The company's forward business is explained through product launches, market growth, pipeline progress, and commercial execution. No mention of "already allocated" money from outside.
NO The hard part is already done: the expensive phase of a major undertaking is finished, and the company is now in the col
Original model output from the research archive. It may be verbose or include the model's working notes.
We need answer YES or NO. Need analyze transcript. Question: Does management convey that company has recently finished expensive/uncertain/heavy phase of major undertaking and now entered collecting phase, with reported results still mostly reflecting paying phase rather than collecting phase? We need use only transcript. Need identify if management describes completed heavy phase and early collecting phase with lag. Look at transcript. Regeneron Q4 2022. They discuss pipeline, launches. Key candidates: aflibercept 8 mg submitted BLA, potential launch late August 2023. Dupixent approvals. Libtayo transaction. Oncology pipeline. COVID antibody. Financial guidance. Question asks about "recently finished expensive, uncertain, or heavy phase of a major undertaking" and now collects. Could be about Libtayo transaction? They acquired worldwide rights to Libtayo from Sanofi. In 2022, they required Sanofi's share of global rights to Libtayo. This was a necessary step. Now they record all R&D and commercial expenses? They have full costs. Not necessarily heavy phase done. Could be about aflibercept 8 mg development: completed pivotal trials, submitted BLA, potential launch late August. Heavy phase (clinical trials) done, now waiting approval/launch. But reported results still EYLEA, not 8 mg. Management says "We are preparing for a potential U.S. launch for aflibercept 8 milligrams in late August" and "over time opportunity to become standard of care." But not yet collecting; payoff is future, not begun. So NO because payoff only promised/projected, not yet begun. Could be about Dupixent: approvals in new indications, launches. Heavy phase? Not really. Could be about oncology: "2022 was crucial year" with Libtayo transaction, pipeline advancing. But still in heavy phase. Could be about "Regeneron Genetics Medicine" etc. Question specifically: "recently finished the expensive, uncertain, or heavy phase of a major undertaking — the part that consumed money, time, and organizational energy — and has now entered the phase where the company COLLECTS on that completed work, with the reported results still mostly reflecting the paying phase rather than the collecting phase?" Need answer YES if management conveys both halves present-tense reality. Look for phrases like "completed", "behind us", "de-risked", "now starting to arrive", "reported results still carry burden".
NO Someone else's clock has started running against them: the company is being paid to solve a problem that is already cost
Original model output from the research archive. It may be verbose or include the model's working notes.
We need to answer YES or NO based on the provided transcript. The question asks whether management describes that their counterparts (customers, partners) are already losing something real and ongoing for as long as they do not have what the company provides, and that this accumulating loss is visible in how those parties are behaving toward the company today. Also, management should convey that this dynamic is generating business meaningful relative to company's size and contribution still ahead. We need to examine the transcript for any such description. Let's scan for relevant phrases. Key products: EYLEA, aflibercept 8mg, Dupixent, Libtayo, oncology pipeline, COVID antibody. Look for descriptions of counterparty losses or urgency. For example, in ophthalmology, they talk about EYLEA and competition. They mention that EYLEA is standard of care, and they are preparing for aflibercept 8mg launch. They talk about patient preference for fewer injections, but not necessarily about counterparts losing money or time. For Dupixent, they talk about launches and uptake, but no mention of counterparts accumulating losses. For oncology, they talk about unmet need and patients, but not about counterparts losing something. The transcript focuses on company progress, pipeline, financials. There is no description of customers or partners currently accumulating losses due to lack of product. The closest might be in COPD, where they talk about selecting patients with eosinophils, but no mention of counterparts losing. For COVID antibody, they talk about protecting vulnerable patients, but not about counterparts losing. The question is specific: management must describe ONE coherent situation with both halves: (1) running meter on the other side, (2) other side acting like meter is running. We need to find such a description in the transcript. Let's read carefully. In the prepared remarks, Leonard talks about strong performance, pipeline progress. No such description. Marion talks about EYLEA, mentions "short-term shift earlier in the quarter where EYLEA was negatively impacted by a temporary increase in use of off-label compounded Avastin" due to closure of co-pay fund. That's about company's loss, not counterparty. They talk about "competitive pressures" but not running meter. George talks about pipeline, but not about counterparty losses. Bob talks about financials.
NO Insiders still discovering the upside: management reports the opportunity keeps revealing itself bigger in live operatio
Original model output from the research archive. It may be verbose or include the model's working notes.
We need answer YES/NO based on transcript. Need evaluate both halves. Let's parse. Question: Does management convey it is STILL DISCOVERING NEW UPSIDE INSIDE BUSINESS THAT IS ALREADY WORKING — that in course of operating, selling, delivering in recent period, company keeps encountering genuine positive surprises about how much more there is for it to do — AND management responding with real attention/resources now? Need use only transcript. Need answer YES if both halves. Let's examine transcript for evidence. Management statements: Len: "Our strong fourth quarter performance kept remarkable year... highlighted by significant achievements..." "fourth quarter 2022 revenue increased 14%... excluding REGEN-COV... underscoring commercial strength and increasing diversity." Then pipeline advances. "Looking ahead, 2023..." Not necessarily discovery. Marion: EYLEA sales, "outpacing total growth of anti-VEGF category for the year." "At end of Q4, EYLEA category share was approaching previous levels of approximately 50% of injections. This followed short-term shift... temporary increase in use of off-label compounded Avastin... We believe we have substantially recovered from issue." That's not positive discovery, it's recovery. Libtayo: "Customer ordering has accelerated following chemotherapy combination approval last November. We are working to maximize launch uptake by increasing depth and breath of prescribers. Early launch indicators are positive community and academic centers have welcomed Libtayo's expanded role..." This is positive but is it "fresh discoveries coming out of live operation"? It's about launch uptake after approval. Management says "Early launch indicators are positive" - that's a positive surprise? But not necessarily "discovering more upside than previously appreciated." It's ordinary confident reporting of strong demand. Dupixent: "global net sales grew 42%... strong growth continuing... DUPIXENT is well positioned to expand market penetration..." "In eosinophilic esophagitis, the launch is going exceptionally well finally offering physicians and their patients a treatment... Patients treated with DUPIXEN have experienced dramatic improvements... we've seen rapid uptake across both gastroenterologists and allergists." This is strong performance, but is it a discovery of new upside? It says launch going exceptionally well, rapid uptake.
NO Operator fluency on fresh ground: management answers probing questions about a new driver with unhesitating operational
Original model output from the research archive. It may be verbose or include the model's working notes.
We need to determine if the dynamic described is present. The question asks about a recently emerged positive element of the business, probed by analysts, and management responds with unhesitating, granular operational command, answering follow-ups with specific present-tense working detail, while conveying that the element's contribution is still early. We need to check the transcript for such a dynamic. The call covers Q4 2022. Recently emerged elements: aflibercept 8mg (not yet launched, but potential launch late August 2023), Libtayo lung cancer approval (Nov 2022), Dupixent new indications (prurigo nodularis, eosinophilic esophagitis), oncology pipeline (fianlimab, odronextamab, linvoseltamab, costim bispecifics), COVID antibody (next-gen). The analysts probe several things. Let's look at the Q&A exchanges. The first question from Tyler Van Buren about EYLEA and Vabysmo competition. That's about long-established core (EYLEA). Not recently emerged. Second question from Matthew Harrison about COPD readout. That's about a pipeline readout, not a current business element. Management talks about expectations, not operational detail. Third question from Carter Gould about APP data with Alnylam. That's about a proof-of-concept, not a current business. Fourth question from Brian Abrams about high-dose aflibercept launch cadence. That's about a potential future launch, not yet current. Management says "we are working on that" and "we will have everything else ready to go" - not granular operational detail. Fifth question from Evan Seigerman about BOREAS interim. Again pipeline. Sixth question from Salveen Richter about oncology portfolio milestones. Management gives strategic overview, not granular operational detail. Seventh question from Mohit Bansal about IL-13 and fibrosis in COPD. Again pipeline. Eighth question from Colin Bristow about COPD readout confidence. Again pipeline. Ninth question from Chris Raymond about geographic atrophy impact on injection volume. That's about market dynamics, not a specific new element. Tenth question from Chris Schott about costim platform and filing pathways. That's about pipeline strategy. Eleventh question from Robyn Karnauskas about MUC16 CD28 safety. Again pipeline. None of these seem to probe a recently emerged positive element that is actually transacting now, with management giving granular operational detail.
NO Compounding evidence: management cites customer behavior, not just customer numbers, as proof the offering is winning
Original model output from the research archive. It may be verbose or include the model's working notes.
We need answer YES/NO. Need analyze transcript. Need determine if management grounds case in observed customer/counterparty behavior from recent period, concrete, current, and treats as core proof with more ahead. Need only transcript. Let's parse. Management discusses EYLEA, Dupixent, Libtayo, aflibercept 8mg, pipeline. Need find behavioral evidence of customers/counterparties doing things. Marion on EYLEA: "EYLEA category share was approaching previous levels of approximately 50% of injections. This followed short-term shift... temporary increase in use of off-label compounded Avastin... not-for-profit patient co-pay assistance fund, which reopened later in quarter. We believe we have substantially recovered from issue." That is about recovery, not necessarily positive behavior. Also "we continue to hear that first nAb use has been modest and results, in some cases, have resulted in patients switching back to other agents, including EYLEA probably most frequently EYLEA." That is observed behavior? Patients switching back to EYLEA. But is it concrete? It's hearsay "we continue to hear" and "in some cases" - not strong. Also management doesn't treat as core proof? Maybe. Dupixent: "strong growth continuing across atopic dermatitis, asthma, nasal polyps with additional contributions from recent launches... rapid uptake in younger populations... meaningful early adoption in prurigo nodularis... DUPIXENT continues to perform well in highly competitive biologic asthma space with steady market share gains and strong growth in total prescriptions and new patient starts. In nasal polyps, DUPIXENT’s differentiated clinical profile continues to drive uptake as leading first-line treatment option... eosinophilic esophagitis launch going exceptionally well... rapid uptake across both gastroenterologists and allergists." This is behavioral evidence? "rapid uptake", "new patient starts", "market share gains" - but not specific concrete behavior? It's more sales/market share metrics, not described as customers doing something revealing preference. Also "launch going exceptionally well" is generic. No specific pattern like reorders, adoption faster, etc. It's company's results. Libtayo: "Customer ordering has accelerated following chemotherapy combination approval last November. We are working to maximize launch uptake by increasing depth and breath of prescribers.
NO Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
Original model output from the research archive. It may be verbose or include the model's working notes.
We need to answer YES or NO based on the transcript. The question asks: does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? That is, does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to check if management speaks about counterparties' business as though it were part of its own, with real substance, and that the company is already inside that growth, and that the counterparties' trajectory is early and large relative to the company. Looking at the transcript, management discusses various partnerships and collaborations. For example, with Sanofi for Dupixent and Libtayo, with Bayer for EYLEA, with Alnylam for siRNA, with Intellia for CRISPR, with Decibel for gene therapy. But are these described as counterparties scaling their own operations that drive Regeneron's volume? The question is about the company's own coming volume being a consequence of those parties' own trajectories. In the transcript, management talks about its own pipeline, its own launches, its own commercial efforts. For instance, Marion McCourt talks about EYLEA sales, Libtayo sales, Dupixent sales, and their own market penetration. George Yancopoulos talks about their own clinical programs. They do mention collaborations, but they don't narrate the counterparties' own scaling as the driver of Regeneron's future revenue. For example, with Alnylam, they talk about initiating Phase 2 studies, but that's their own development. They don't say "Alnylam is expanding their manufacturing capacity, which will drive our sales." The counterparties are partners in development, not customers whose expansion drives Regeneron's volume. The question specifically asks about customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves. In the transcript, the company's revenue comes from product sales (EYLEA, Dupixent, Libtayo) and collaboration revenue (sharing profits with Sanofi, Bayer, Roche).
NO Earned edge, pressed harder: management credits current results to an advantage the company built itself, and is reinves
Original model output from the research archive. It may be verbose or include the model's working notes.
We need to determine if management attributes current results to a specific self-built advantage and describes committing resources to extend it now. Looking at the transcript: Len mentions "our internal R&D capabilities which has historically generated a high rate of return" and "approximately 35 pipeline candidates currently progressing through clinical trials." That's a general statement. But is there a specific advantage? George talks about various pipeline programs. However, the question asks about CURRENT results or business wins. The company's current revenue drivers are EYLEA, Dupixent, Libtayo. Are they attributing current wins to a specific self-built advantage? For example, EYLEA is a product they developed. But do they say "we built this advantage and now we are investing to extend it"? They mention aflibercept 8 mg as a potential new standard, but that's not yet approved. They talk about Dupixent's mechanism blocking IL-4/IL-13 as differentiated. But is that a self-built advantage? They developed it. They also mention "our internal R&D engine" but that's generic. The key is: do they name a specific advantage that is producing current business and then describe committing resources to extend that same advantage now? For instance, they might say "our R&D engine has produced these drugs, and we are investing more in R&D to produce more." But that's generic. They do mention "we are preparing for a potential U.S. launch for aflibercept 8 milligrams" - that's future. They mention "we expect Dupixent to continue to strengthen" - that's expectation. Look for a specific advantage like "our proprietary VelociGene technology" or something. They don't mention that. They mention "Regeneron Genetics Center" but not as a current business driver. The question asks: "does management attribute the company's CURRENT results or current business wins to a SPECIFIC ADVANTAGE THE COMPANY ITSELF BUILT — and describe that it is NOW committing additional resources to widen or extend that same advantage while it is working?" In the transcript, they talk about their pipeline and R&D, but they don't explicitly say "our current sales are due to our unique X, and we are now investing more in X." They do say "our strategy remains focused on investing in our internal R&D capabilities which has historically generated a high rate of return." That is a general statement.
NO Bet-the-company financing already spent on hard assets that are nearly finished
Original model output from the research archive. It may be verbose or include the model's working notes.
We need to determine if the transcript describes a situation where the company is in the last stretch before its biggest-ever productive thing switches on, with funding already secured, the build large relative to company, and current numbers reflecting a smaller predecessor business. Let's analyze the transcript. The company is Regeneron, a biopharmaceutical company. They discuss various products: EYLEA, Dupixent, Libtayo, and pipeline candidates. They mention aflibercept 8 mg for wet AMD and DME, with a potential U.S. launch in late August 2023. They also mention odronextamab and linvoseltamab for regulatory submissions in second half of 2023. They have a next-generation COVID-19 antibody in development. But the question is about a "productive thing" that is large relative to the whole company, with funding already committed, and the company is about to start up. The transcript does not describe a major capital project like a plant or mine. It's a pharmaceutical company with ongoing products and pipeline. The company is already generating significant revenue from existing products (EYLEA, Dupixent, Libtayo). The new things like aflibercept 8 mg are product launches, but they are not described as a massive build that dwarfs the company. The company is already large and diversified. The transcript does not convey that the company is currently a smaller predecessor business about to be transformed by a single huge undertaking. Instead, it's a mature company with multiple products and a pipeline. The question asks: "On this call, does management describe the company as being in the LAST STRETCH BEFORE ITS BIGGEST-EVER PRODUCTIVE THING SWITCHES ON?" That would require a clear description of a massive project. The transcript does not have that. It's about ongoing operations and pipeline progress. There is no mention of a huge capital expenditure that is nearly complete and will dwarf current operations. The company is already large. So the answer is NO. We need to be careful: The question is about a "productive thing" that is large relative to the entire company. The company's current revenue is billions. A new product like aflibercept 8 mg might be significant but not described as a transformative build. Also, the funding is not discussed as a separate issue; the company has cash and is spending on R&D. But the essence is not there. Thus, answer NO.
NO Reordering the pecking order: management describes the company winning on a stage where it used to be too small to play
Original model output from the research archive. It may be verbose or include the model's working notes.
We need to determine if management conveys that the company has moved up a tier in its market, and that this is already producing real results, but early. The transcript discusses various products and pipeline. Key points: Libtayo was approved for first-line non-small cell lung cancer, making it only the second PD-1/PD-L1 antibody in that setting regardless of histology or PD-L1 expression. This is a significant expansion. Also, they acquired full rights to Libtayo from Sanofi. They are now competing in oncology with a broader indication. They also have aflibercept 8 mg for wet AMD and DME, which could become new standard of care. But is that a tier change? They already had EYLEA as standard of care. So that's not moving up a tier. The question is about the company now competing and winning at a level of the market that used to be above it. For example, being treated as a legitimate contender in situations that previously would have gone to bigger players. In the transcript, Len says: "We also made several important advances across our pipeline during the quarter, notably the submission of a Biologic License Application for aflibercept 8 milligrams... Additionally, we received FDA approval for Libtayo in combination with chemotherapy as a first line treatment for advanced non-small cell lung cancer, making Libtayo only the second PD-1 or PD-L1 antibody approved in this setting, regardless of the patient’s histology or PD-L1 expressions level." That is a significant achievement, but is it a tier change? They are now competing with the likes of Merck's Keytruda, which is the dominant PD-1. Being the second approved in that setting is a big deal. But does management convey that they have moved up a tier? They say "only the second" - that suggests they are now among the top players. Also, they acquired full rights to Libtayo, which was previously shared with Sanofi. That gives them more control. But the question specifically asks: "does management convey that the company has recently begun to be treated as a legitimate contender in situations, against rivals, or for business that previously would have gone to bigger, more established, or more entrenched players, and that this has already produced real results in the current period?" Look for a change in tier, already real, and early. In the transcript, there is a section about Libtayo in lung cancer.
NO Answers go deeper than the script: questioning keeps surfacing new concrete detail behind a positive development
Original model output from the research archive. It may be verbose or include the model's working notes.
We need to determine if there is a positive, current development discussed in the Q&A that yields more concrete operating detail than the prepared remarks. The call covers many topics: EYLEA, Dupixent, Libtayo, aflibercept 8mg, oncology pipeline (LAG-3, costim bispecifics, CD3 bispecifics), COPD, COVID antibody, etc. We need to see if in the Q&A, management provides additional specifics about a positive development that were not in the prepared remarks. The question asks for a single development that is probed across multiple exchanges with additive detail. Let's review the Q&A exchanges: 1. Tyler Van Buren asks about EYLEA marketplace, specifically about Roche's Vabysmo? Actually he asks about "what you are seeing in the marketplace with respect to [indiscernible]" - likely about Vabysmo competition. Marion responds: EYLEA performance strong, growing 8% to $6.3B, competitive performance. She mentions that first nAb use has been modest and results sometimes lead to switching back to EYLEA. She also mentions enthusiasm for aflibercept 8mg launch. This is somewhat general, not much new detail beyond prepared remarks. Prepared remarks already said EYLEA sales, category share, etc. The answer adds that patients switch back to EYLEA, but that's not very concrete. 2. Matthew Harrison asks about COPD and what is clinically meaningful. George responds about powering, looking at exacerbations and lung function, mentions Dupixent in asthma. This is general, no new specifics about the COPD trial itself. Prepared remarks already said BOREAS readout expected first half, etc. No new detail. 3. Carter Gould asks about APP data with Alnylam, whether it's proof of concept or product opportunity. George responds that it's a platform enabler, proof of concept for CNS delivery. This is about a future program, not a current positive development with concrete operating detail. It's early stage, no specifics about results. 4. Brian Abrams asks about high-dose aflibercept launch cadence, pre-filled syringe, J-code, strategy. Len responds that they are working on it, initial launch with vial, then PFS. Marion says they have experienced team, will be ready. This is about a future launch, not current development. No concrete details about actual operations. 5. Evan Seigerman asks about oncology portfolio milestones, specifically PSMAxCD28. Len lists submissions, data, etc.
NO Relationships widening on the customers' initiative, with the numbers still catching up
Original model output from the research archive. It may be verbose or include the model's working notes.
We need to answer YES or NO based on the transcript. The question asks: Does management describe that SEVERAL of the company's EXISTING commercial relationships have RECENTLY GOTTEN BIGGER — counterparties the company had already won (customers, accounts, partners, distributors, members, or programs) that have, in the recent period, chosen to take a wider or deeper commitment than they had before — AND does management convey that the reported results reflect only the early part of these widenings, with most of their contribution still ahead? We need to find evidence in the transcript. Look for mentions of existing relationships expanding, e.g., existing customers adding more, partners extending scope, etc. Also, management should say that the reported results only partially reflect these expansions, with more to come. Scan the transcript. There are mentions of Dupixent approvals in new indications, geographies, younger populations. That could be expanding existing relationships? But that's more about new patients, not necessarily existing counterparties widening. Also, Libtayo expansion into new indications, but that's new patients. The question specifically asks about existing commercial relationships (customers, accounts, partners, distributors) getting bigger. For example, existing partners like Sanofi, Bayer, Roche? But those are collaborations, not necessarily widening. The transcript mentions "we also recognized a $50 million sales-based milestone in the fourth quarter of 2022 due to achievement of $2.5 billion of ex-U.S. sales of antibody collaboration products on a rolling 12-month basis." That's a milestone, not a widening. Look for phrases like "existing customers adding" or "accounts that started with one product now taking additional ones". There is mention of Dupixent expanding into new indications, which might mean existing patients or new patients? But the question is about counterparties (like hospitals, clinics, distributors) choosing to take more. The transcript doesn't seem to explicitly describe multiple existing relationships widening. There is mention of "we continue to see steady growth in utilization in prescribers" for Libtayo, but that's not necessarily existing relationships widening. Also, the question asks if management conveys that the reported results reflect only the early part of these widenings. I don't see that.
NO Proven engine, fuel already in the tank: a working growth driver plus already-held means to multiply it
Original model output from the research archive. It may be verbose or include the model's working notes.
We need answer YES/NO. Need analyze transcript. Need determine if management describes both: (1) proven already-producing growth engine still small relative to room, with specific driver already generating real business and small captured share; (2) means to multiply already in company's hands, already underway/resources. Need same part of business connected present-tense story. Let's parse transcript. Management discusses Dupixent, EYLEA, Libtayo, pipeline. Need find if they describe a growth engine with small share and means to scale already in hands. Potential candidates: Dupixent. Marion: "DUPIXENT is well positioned to expand market penetration and drive revenue growth across established new and potential future indications in 2023 and beyond." Atopic dermatitis rapidly grow, etc. But is it small relative to room? They mention addressable population increased to over 7 million patients globally. But do they convey how little captured? Not explicitly. They say "strong growth continuing", "rapid uptake", "leading market position", "well positioned to expand market penetration". But no specific "small part" captured. Also means to multiply? They have approvals, new indications, geographies, younger populations. But not necessarily "already in company's hands" scaling same driver? They have regulatory approvals already? They mention potential approvals in 2023. But Dupixent is already large ($8.7B). Not small relative to room? They don't quantify share. Libtayo: "Libtayo continues to see steady growth... Customer ordering accelerated following chemotherapy combination approval... Early launch indicators positive... more than 200,000 new cases of lung cancer per year in U.S. alone for which Libtayo is important treatment option." This is a growth engine? It is already generating revenue ($169M quarter, growing 44%). Is it small relative to room? They mention 200,000 new cases, but not how little captured. They say "we are working to maximize launch uptake by increasing depth and breadth of prescribers." That implies early. But no explicit "small part". Means to multiply? They have global commercial footprint, targeted approach, approvals. But not clearly "already in hands" scaling? They have Libtayo rights, commercial infrastructure. But not connected as "already producing and small share". Aflibercept 8 mg: Not yet approved, launch late August.
NO Demand arrived first, the company is growing to meet it
Original model output from the research archive. It may be verbose or include the model's working notes.
We need answer YES/NO. Need analyze transcript. Need determine both halves present connected present-tense story. Question asks: On this call, does management convey BOTH: (1) NEW DEMAND IS ALREADY SHOWING UP. Management points to demand for what company sells that recently arrived/stepped up and REAL TODAY — actual orders, customers, sign-ups, bookings, volumes, usage, patients, projects, buying activity began/accelerated recent period described observed fact. (2) COMPANY ACTIVELY GROWING ITSELF TO SERVE IT. In response to arriving demand, management describes company presently making itself bigger/more capable — adding capacity, production, inventory, locations, equipment; hiring, training, expanding teams; extending shifts, output, service coverage; standing up systems, facilities, supply; scaling ability to deliver — described already underway/decided and being executed now, not merely planned. Demand running ahead of company built, reported results reflect catching up. Need use only transcript. Need answer YES or NO. Let's parse transcript. Management discusses strong performance, revenue growth, Dupixent, EYLEA, Libtayo, pipeline. Need find if they explicitly connect current demand to current expansion of company capability. Potential candidates: Bob Landry guidance: 2023 SG&A spend increase due to full year impact Libtayo commercialization, build-out international commercial infrastructure in select markets, higher headcount. R&D expense increase due to late-stage pipeline, clinical manufacturing activities, higher headcount. Capital expenditures support expansion manufacturing facilities, including construction fill/finish facility and expansion R&D facilities. This is expansion but is it in response to NEW DEMAND already showing up? They mention "higher headcount to support our growing organization" and "build-out of our international commercial infrastructure" but not specifically because demand arrived. Also "incremental costs to fully support global commercialization of Libtayo" and "higher contributions to not-for-profit patient systems organization." But is demand already showing up? Libtayo sales growing 44%, Dupixent growing, EYLEA. But expansion described as "full year impact" and "build-out" maybe in response to growth. However question requires both halves connected: arriving demand is stated reason for current expansion.
NO Answers go deeper than the script: questioning keeps surfacing new concrete detail behind a positive development — compa
Original model output from the research archive. It may be verbose or include the model's working notes.
We need to evaluate two gates based only on the transcript. Gate 1: Is there a positive current development that management presents as going well, and in Q&A, management adds more concrete operating detail than in prepared remarks? We need to see if across multiple exchanges, management provides fresh specifics. Gate 2: Is the primary engine of that development something the company itself created and controls, not external tailwinds? Let's identify the main positive developments discussed. The call covers EYLEA, Dupixent, Libtayo, aflibercept 8mg, oncology pipeline, etc. The Q&A focuses on several topics: EYLEA market share, COPD readout, aflibercept 8mg launch, costim bispecifics, etc. We need to see if any positive development is probed with additive detail. Let's look at the Q&A. First question: EYLEA market share. Marion responds with some detail about EYLEA performance, mentions Vabysmo competition, but not much new beyond prepared remarks. She says "we continue to hear that first nAb use has been modest and results, in some cases, have resulted in patients switching back to other agents, including EYLEA probably most frequently EYLEA." That's some detail but not extensive. Second question: COPD. George talks about powering for clinically meaningful benefit, but doesn't give specifics. Len says they are blinded to interim analysis. Not much additive. Third question: aflibercept 8mg launch. Len says they are working on pricing, rollout, etc., but no specifics. Marion says they have a highly experienced team, but no new details. Fourth question: oncology portfolio. George gives a long answer about the strategy, but it's more about the pipeline and potential, not current operating details. He mentions "we are going to be rolling out data from these combinations" but that's future. Fifth question: COPD again. Len says they are data-driven, blinded, etc. No new specifics. Sixth question: VEGF retinal market and geographic atrophy. Len and George discuss practice dynamics, but not specific to a current development. Seventh question: costim platform. Len and George discuss potential accelerated approval, but again future. Eighth question: MUC16 and CD28. George discusses safety and dose escalation, but again more about the program's status. Overall, the Q&A does not seem to produce more concrete operating detail than the prepared remarks.
We need answer only YES or NO. Need evaluate both gates. Need use only transcript. We need determine if Gate 1: positive current development, Q&A adds more concrete operating detail than prepared remarks. Gate 2: development chiefly company-created and controlled, not external. Let's analyze transcript. Prepared remarks highlight: EYLEA sales, Dupixent asthma approval, Libtayo launch, pipeline. Q&A topics: Dupixent payor access, asthma market, adolescent, DTC, persistence; EYLEA growth and higher dose; NGF; bluebird; peanut allergy. Gate 1: Need find positive current development where Q&A produces more concrete operating detail than prepared remarks across multiple exchanges. Let's examine Q&A. First Q: Dupixent payor access for asthma vs AD. Marion: early days, three weeks, majority market coverage. Not much new. Second Q: Dupixent market opportunity moderate eosinophilic asthma, low biologic penetration. Len: self-administered product. Marion: physicians use on tougher patients first, anecdotal reports positive, etc. George: clinical profile. Not much concrete new. Third Q: Dupixent peanut allergy study with Aimmune. Len gives science, not operational detail. No. Fourth Q: Dupixent adolescent indication and asthma payor. Marion: uptake similar/faster, reasons. No concrete numbers. Fifth Q: Dupixent DTC, patient mix, persistence/refill rates. Marion: persistence 80% at 12 months, first script refill over 90%, DTC since August. This is concrete detail not in prepared remarks? Prepared remarks mentioned DTC launched, early results. Q&A adds persistence/refill rates. But only one exchange? Need multiple exchanges. Other Q&A about EYLEA. Sixth Q: EYLEA 2019 growth, higher dose. George: higher dose rationale, no specifics. Len: market demographics, competition, diabetic retinopathy. Not much. Seventh Q: NGF safety and bluebird. Len: dose, VSMB, etc. George: bluebird collaboration. Not much. So Gate 1: Is there a positive current development where Q&A adds more concrete operating detail than prepared remarks? The Dupixent persistence/refill rates are new specifics, but only in one exchange. Other Q&A mostly repeats or general. Need "across multiple exchanges" additive. Not really. Also prepared remarks already had DTC, launch, etc. Q&A doesn't add much. So Gate 1 likely NO. Gate 2: If Gate 1 NO, answer NO. But let's still consider.
We need answer only YES or NO. Need evaluate both gates. Need use only transcript. We need determine if there is positive current development with Q&A adding more concrete operating detail than prepared remarks. And improvement filter: engine company-controlled vs external. Let's parse call. Prepared remarks: EYLEA growth, Dupixent launch, Kevzara, Praluent outcomes upcoming, cemiplimab, bispecifics, etc. Q&A topics: immuno-oncology strategy, SG&A, bispecific dosing, fasinumab, Kevzara, ODYSSEY, EYLEA competition, Dupixent payer process and pediatric. Need see if any positive current development probed with additive specifics. Potential candidates: Dupixent launch? Prepared remarks gave numbers: Q4 sales $139M, 56% increase, 500 new-to-brand scripts, 8,500 prescribers, renewal >90%. Q&A on Dupixent: Len discusses payer process, access, #deniedRx, but not much new operating detail. He says 80-85% plans made decisions, but that's somewhat new? Actually prepared remarks mentioned payer processes frustrations, but not specific coverage percentage. However Q&A answer is about problems/access, not really adding positive operational detail. Also pediatric: George says Phase 3 fully enrolled, submit sBLA by end of year. That was already in prepared remarks? Prepared: "first of these in children between ages 12 and 17 is fully enrolled, and we expect to report data by midyear and submit supplemental BLA in second half." Q&A repeats. So not additive. Bispecifics: Prepared remarks: lead CD20/CD3 continues, dosing levels achieved 50% response rates without DLTs, continue dose escalation, expect two more candidates. Q&A George gives more detail: doses 5-8 mg, 12 mg, now beyond, gradual dose escalation, advantages. This is additive and substantive about actual clinical development. Is this a positive current development? Yes, bispecific program showing efficacy. But is it "current development" in business? It's clinical progress, not commercial. The gate says "actual business activity, demand, execution, or progress already happening now" - clinical progress counts? It says "development" in company's business, could include pipeline. But Q&A adds specifics about dosing and responses. However, is it multiple exchanges? Only one question about bispecifics (Geoff asked dosing). The rest Q&A not about that.
Showing the latest 18 of 230 archived research questions.
These archived questions are separate from the newer 500-check scan above.
REGN call history
Open a quarter only when you want its detailed evidence.
D Q1 2026 · Weak call · 2026-04-29Management lowered guidance against mixed demand signals and contracting margins. The delivery was rich in specifics, promotional in tone.
F Q1 2025 · Very weak call · 2026-02-05Management lowered guidance against mixed demand signals and contracting margins. The delivery was unusually candid, rich in specifics.
View the 20 core call-quality checks
D Q2 2025 · Weak call · 2026-02-05Management lowered guidance against mixed demand signals and contracting margins. The delivery was unusually candid, rich in specifics.
View the 20 core call-quality checks
D Q4 2024 · Weak call · 2026-02-05Management held guidance steady against mixed demand signals. The delivery was rich in specifics, frequently evasive, promotional in tone.
View the 20 core call-quality checks
C Q3 2024 · Caution · 2026-02-05Management held guidance steady against accelerating demand and contracting margins. The delivery was unusually candid, rich in specifics.
View the 20 core call-quality checks
C+ Q4 2025 · Mixed call · 2026-01-30Management held guidance steady against mixed demand signals and contracting margins. The delivery was unusually candid, rich in specifics, promotional in tone.
View the 20 core call-quality checks
D Q3 2025 · Weak call · 2025-10-28Management held guidance steady against mixed demand signals and contracting margins. The delivery was rich in specifics.
View the 20 core call-quality checks
View 38 earlier calls
| Call | Date | Grade | Guidance | Demand | Margins | Candor | Evasion |
|---|---|---|---|---|---|---|---|
| Q1 2025 | 2025-04-29 | D | lowered | mixed | contracting | 7/9 | 4/9 |
| Q4 2024 | 2025-02-04 | C+ | maintained | mixed | expanding | 7/9 | 4/9 |
| Q3 2024 | 2024-10-31 | C | maintained | mixed | stable | 7/9 | 4/9 |
| Q2 2024 | 2024-08-01 | C | lowered | accelerating | contracting | 7/9 | 2/9 |
| Q1 2024 | 2024-05-02 | B | maintained | accelerating | expanding | 7/9 | 2/9 |
| Q4 2023 | 2024-02-02 | C+ | maintained | accelerating | expanding | 6/9 | 3/9 |
| Q3 2023 | 2023-11-02 | C | maintained | accelerating | expanding | 6/9 | 4/9 |
| Q2 2023 | 2023-08-03 | B | maintained | stable | expanding | 8/9 | 2/9 |
| Q1 2023 | 2023-05-04 | D | maintained | mixed | contracting | 6/9 | 5/9 |
| Q4 2022 | 2023-02-03 | C | maintained | accelerating | stable | 6/9 | 4/9 |
| Q3 2022 | 2022-11-03 | C+ | maintained | accelerating | expanding | 6/9 | 3/9 |
| Q2 2022 | 2022-08-03 | C | raised | accelerating | expanding | 6/9 | 4/9 |
| Q1 2022 | 2022-05-04 | B+ | raised | accelerating | stable | 7/9 | 3/9 |
| Q4 2021 | 2022-02-04 | C+ | maintained | accelerating | stable | 6/9 | 3/9 |
| Q3 2021 | 2021-11-04 | C | lowered | accelerating | expanding | 7/9 | 4/9 |
| Q2 2021 | 2021-08-05 | B | maintained | accelerating | expanding | 7/9 | 2/9 |
| Q1 2021 | 2021-05-06 | C | maintained | accelerating | expanding | 6/9 | 3/9 |
| Q4 2020 | 2021-02-05 | C | maintained | accelerating | expanding | 6/9 | 4/9 |
| Q3 2020 | 2020-11-05 | B | maintained | accelerating | expanding | 7/9 | 2/9 |
| Q2 2020 | 2020-08-05 | B+ | raised | mixed | stable | 7/9 | 3/9 |
| Q1 2020 | 2020-05-05 | C+ | maintained | mixed | expanding | 7/9 | 3/9 |
| Q4 2019 | 2020-02-06 | C | none | accelerating | expanding | 6/9 | 4/9 |
| Q3 2019 | 2019-11-05 | B | raised | accelerating | expanding | 6/9 | 4/9 |
| Q2 2019 | 2019-08-06 | C+ | maintained | accelerating | expanding | 7/9 | 4/9 |
| Q1 2019 | 2019-05-07 | D | maintained | accelerating | contracting | 7/9 | 4/9 |
| Q4 2018 | 2019-02-06 | C | maintained | accelerating | expanding | 6/9 | 3/9 |
| Q3 2018 | 2018-11-06 | C | lowered | accelerating | expanding | 7/9 | 3/9 |
| Q2 2018 | 2018-08-02 | C | lowered | accelerating | expanding | 7/9 | 3/9 |
| Q1 2018 | 2018-05-03 | C | lowered | accelerating | stable | 6/9 | 3/9 |
| Q4 2017 | 2018-02-08 | C | maintained | accelerating | stable | 7/9 | 3/9 |
| Q3 2017 | 2017-11-08 | C+ | lowered | accelerating | stable | 7/9 | 2/9 |
| Q2 2017 | 2017-08-03 | B+ | raised | accelerating | stable | 7/9 | 3/9 |
| Q1 2017 | 2017-05-04 | C | lowered | accelerating | contracting | 6/9 | 3/9 |
| Q4 2016 | 2017-02-09 | D | maintained | slowing | stable | 6/9 | 4/9 |
| Q3 2016 | 2016-11-04 | F | lowered | mixed | stable | 6/9 | 5/9 |
| Q2 2016 | 2016-08-04 | C+ | maintained | accelerating | contracting | 7/9 | 2/9 |
| Q1 2016 | 2016-05-05 | D | raised | mixed | stable | 7/9 | 5/9 |
| Q4 2015 | 2016-02-09 | C | maintained | mixed | contracting | 7/9 | 4/9 |